% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Harewood:288729,
      author       = {R. Harewood and J. A. Rothwell and J. Bešević and V.
                      Viallon and D. Achaintre and A. Gicquiau and S. Rinaldi and
                      R. Wedekind and C. Prehn and J. Adamski and J. A. Schmidt
                      and I. Jacobs and A. Tjønneland and A. Olsen and G. Severi
                      and R. Kaaks$^*$ and V. Katzke$^*$ and M. B. Schulze and M.
                      Prada and G. Masala and C. Agnoli and S. Panico and C.
                      Sacerdote and P. G. Jakszyn and M.-J. Sánchez and J.
                      Castilla and M.-D. Chirlaque and A. A. Atxega and B. van
                      Guelpen and A. K. Heath and K. Papier and T. Y. N. Tong and
                      S. A. Summers and M. Playdon and A. J. Cross and P.
                      Keski-Rahkonen and V. Chajès and N. Murphy and M. J.
                      Gunter},
      title        = {{A}ssociation between pre-diagnostic circulating lipid
                      metabolites and colorectal cancer risk: a nested
                      case-control study in the {E}uropean {P}rospective
                      {I}nvestigation into {C}ancer and {N}utrition ({EPIC}).},
      journal      = {EBioMedicine},
      volume       = {101},
      issn         = {2352-3964},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2024-00438},
      pages        = {105024},
      year         = {2024},
      abstract     = {Altered lipid metabolism is a hallmark of cancer
                      development. However, the role of specific lipid metabolites
                      in colorectal cancer development is uncertain.In a
                      case-control study nested within the European Prospective
                      Investigation into Cancer and Nutrition (EPIC), we examined
                      associations between pre-diagnostic circulating
                      concentrations of 97 lipid metabolites (acylcarnitines,
                      glycerophospholipids and sphingolipids) and colorectal
                      cancer risk. Circulating lipids were measured using targeted
                      mass spectrometry in 1591 incident colorectal cancer cases
                      $(55\%$ women) and 1591 matched controls. Multivariable
                      conditional logistic regression was used to estimate odds
                      ratios (ORs) and $95\%$ confidence intervals (CIs) for
                      associations between concentrations of individual lipid
                      metabolites and metabolite patterns with colorectal cancer
                      risk.Of the 97 assayed lipids, 24 were inversely associated
                      (nominally p < 0.05) with colorectal cancer risk.
                      Hydroxysphingomyelin (SM (OH)) C22:2 (ORper doubling 0.60,
                      $95\%$ CI 0.47-0.77) and acylakyl-phosphatidylcholine (PC
                      ae) C34:3 (ORper doubling 0.71, $95\%$ CI 0.59-0.87)
                      remained associated after multiple comparisons correction.
                      These associations were unaltered after excluding the first
                      5 years of follow-up after blood collection and were
                      consistent according to sex, age at diagnosis, BMI, and
                      colorectal subsite. Two lipid patterns, one including 26
                      phosphatidylcholines and all sphingolipids, and another 30
                      phosphatidylcholines, were weakly inversely associated with
                      colorectal cancer.Elevated pre-diagnostic circulating levels
                      of SM (OH) C22:2 and PC ae C34:3 and lipid patterns
                      including phosphatidylcholines and sphingolipids were
                      associated with lower colorectal cancer risk. This study may
                      provide insight into potential links between specific lipids
                      and colorectal cancer development. Additional prospective
                      studies are needed to validate the observed
                      associations.World Cancer Research Fund (reference:
                      2013/1002); European Commission (FP7: BBMRI-LPC; reference:
                      313010).},
      keywords     = {Acylcarnitines (Other) / Colorectal cancer (Other) /
                      Glycerophospholipids (Other) / Lipids (Other) / Metabolomics
                      (Other) / Sphingolipids (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38412638},
      doi          = {10.1016/j.ebiom.2024.105024},
      url          = {https://inrepo02.dkfz.de/record/288729},
}